It’s been about six weeks since Credit Suisse initiated coverage of PTC Therapeutics, Inc. PTCT 4.69% with an Outperform rating and $36 price target on the stock. Now, less than two months later, the stock is down more than 76 percent and trading at $5.70 per share.

On February 23, PTC disclosed that it had received a “Refuse to File” letter from the FDA concerning its new drug application to clear Translarna for treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). The news sent PTC’s stock plummeting and Wall Street analysts backpedaling.

The timing of Credit Suisse’s initiation was embarrassingly bad, but the firm wasn’t the only one on Wall Street that completely whiffed on PTC. Prior to February 23, Citi had a $90 price target on PTC, Oppenheimer had a $111 target and Cowen had a $120 target on the stock as recently as February 26.

Jefferies analyst Gena Wang, who lowered the firm’s target from $18 to $12 on February 24, is…

Click here to continue reading

Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!